The in vitro experiments found that the inhibition of USP13 expression could significantly inhibit the progression of ovarian cancers and enhance the sensitivity of cancer cells to treatment with PI3K/AKT inhibitors. This evidence concerns the gene AKT1 and ovarian carcinoma.